How have ERNA shares performed in 2024?

Eterna Therapeutics' stock was trading at $1.7950 on January 1st, 2024. Since then, ERNA stock has increased by 11.4% and is now trading at $2.00. View the best growth stocks for 2024 here .

When is Eterna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our ERNA earnings forecast .

How were Eterna Therapeutics' earnings last quarter?

Eterna Therapeutics Inc. (NASDAQ:ERNA) issued its quarterly earnings data on Thursday, March, 14th. The company reported ($1.14) earnings per share for the quarter. The company earned $0.02 million during the quarter.

Who are Eterna Therapeutics' major shareholders?

Eterna Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Sippican Capital Advisors (1.35%) and Avidian Wealth Solutions LLC (0.27%). Insiders that own company stock include John D Halpern and Nicholas Jason Singer. View institutional ownership trends .

How do I buy shares of Eterna Therapeutics?

Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ERNA

Eterna Therapeutics (ERNA) Stock Price, News & Analysis

→ What President Biden's new law means for investors (From Stansberry Research) (Ad)

Free ERNA Stock Alerts

$2.00

0.00 (0.00%)

(As of 10:01 AM ET)

Compare

Today's Range: $2.00
▼
$2.12
50-Day Range: $1.74
▼
$2.44
52-Week Range: $0.84
▼
$2.99

Volume: 400 shs
Average Volume: 9,373 shs
Market Capitalization: $10.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Ad Stansberry Research

Everybody laughed when he recommended Netflix

"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined.

Click here to see how it could become the No. 1 investment of the next decade.

About Eterna Therapeutics Stock (NASDAQ:ERNA)

Eterna Therapeutics Inc. operates as a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. The company was formerly known as Brooklyn ImmunoTherapeutics, Inc. and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.

ERNA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ERNA Stock News Headlines

May 10, 2024 | globenewswire.com

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

May 8, 2024 | globenewswire.com

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

May 7, 2024 | finance.yahoo.com

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus

March 27, 2024 | finance.yahoo.com

Q4 2023 Cognition Therapeutics Inc Earnings Call

March 26, 2024 | msn.com

Viking Therapeutics' experimental tablet helps reduce weight in small study

March 15, 2024 | investorplace.com

ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023

February 23, 2024 | benzinga.com

Eterna Therapeutics Stock (NASDAQ:ERNA) Dividends: History, Yield and Dates

February 20, 2024 | finance.yahoo.com

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

February 20, 2024 | globenewswire.com

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

January 12, 2024 | msn.com

Eterna Therapeutics files to sell 18.2M shares for holders

January 3, 2024 | finance.yahoo.com

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

December 21, 2023 | finance.yahoo.com

Eterna Therapeutics Appoints Sanjeev Luther as President and CEO

December 20, 2023 | msn.com

Eterna Therapeutics names Sanjeev Luther as CEO

December 20, 2023 | finance.yahoo.com

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

December 15, 2023 | msn.com

Eterna Therapeutics launches convertible debt and warrant financing of up to $9.2M

December 14, 2023 | finance.yahoo.com

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

December 6, 2023 | markets.businessinsider.com

Treadwell Announces Strategic Pipeline Prioritization and Leadership Transitions

November 1, 2023 | finance.yahoo.com

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

October 30, 2023 | markets.businessinsider.com

Calidi Biotherapeutics Names Andrew Jackson CFO

October 30, 2023 | marketwatch.com

Calidi Biotherapeutics Names Andrew Jackson Chief Financial Officer

October 5, 2023 | markets.businessinsider.com

Positive Clinical Outcomes and Continued Genentech Support Bolster Buy Rating for Lineage Cell Therapeutics: An Analysis of OpRegen’s Potential

September 13, 2023 | uk.finance.yahoo.com

Stem Cell Therapy Contract Manufacturing market is projected to grow at a CAGR of 12.4% by 2033: Visiongain

September 8, 2023 | finance.yahoo.com

Insider Stock Buying Reaches US$2.7m On Eterna Therapeutics

September 6, 2023 | finance.yahoo.com

Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies

See More Headlines

Company Calendar

Last Earnings: 3/14/2024
Today: 5/20/2024
Next Earnings (Estimated): 8/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ERNA
CUSIP: N/A
CIK: 748592
Web: www.brooklynitx.com
Phone: (212) 582-1199
Fax: 760-438-3505
Employees: 8
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($4.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-21,670,000.00
Net Margins: N/A
Pretax Margin: -19,915.65%
Return on Equity: -1,466.71%
Return on Assets: -46.26%

Debt

Debt-to-Equity Ratio: 3.03
Current Ratio: 0.79
Quick Ratio: 0.79

Sales & Book Value

Annual Sales: $70,000.00
Price / Sales: 154.57
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.41 per share
Price / Book: 4.88

Miscellaneous

Outstanding Shares: 5,410,000
Free Float: 3,493,000
Market Cap: $10.82 million
Optionable: No Data
Beta: 4.31

Key Executives

Ms. Sandra M. Gurrola (Age 57)
Principal Financial & Accounting Officer and Senior VP of Finance
Comp: $305.88k
Mr. Sanjeev Luther (Age 62)
CEO, President & Director
Ms. Dorothy J. Clarke (Age 58)
General Counsel & Director
Ms. Megan Yung
Chief Strategy Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ERNA Stock Analysis - Frequently Asked Questions

How have ERNA shares performed in 2024?: Eterna Therapeutics' stock was trading at $1.7950 on January 1st, 2024. Since then, ERNA stock has increased by 11.4% and is now trading at $2.00.
View the best growth stocks for 2024 here.
When is Eterna Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024.
View our ERNA earnings forecast.
How were Eterna Therapeutics' earnings last quarter?: Eterna Therapeutics Inc. (NASDAQ:ERNA) issued its quarterly earnings data on Thursday, March, 14th. The company reported ($1.14) earnings per share for the quarter. The company earned $0.02 million during the quarter.

Who are Eterna Therapeutics' major shareholders?: Eterna Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Sippican Capital Advisors (1.35%) and Avidian Wealth Solutions LLC (0.27%). Insiders that own company stock include John D Halpern and Nicholas Jason Singer.
View institutional ownership trends.
How do I buy shares of Eterna Therapeutics?: Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ERNA) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings